DeepLife

DeepLife

Biotechnologie

Paris, Ile-de-France 2 290 abonnés

AI for digital twin of cells

À propos

DeepLife is an early stage startup founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, backed by international investors, developing the first SaaS platform for Digital Twin of cells. While we are able to design and build incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge. However, recent technological improvements, notably in biochemistry, recently enabled the construction of databases with millions of quantitative cell activity measures, covering multiple diseases. The DeepLife team develops a SaaS platform combining state-of-the-art deep learning algorithms on multi-omics sequencing data, public and private cell atlases, and proprietary deep learning-based cell engineering tools. Our goal is to supplement in vitro testing with in silico simulations and rapidly discover molecular triggers to efficiently engineer cell behavior. We are working closely with biotech and pharmaceutical companies to accelerate their target identification processes. We are also collaborating actively with the academic community by publishing papers and providing open access to our platform’s features and data.

Site web
https://deeplife.co
Secteur
Biotechnologie
Taille de l’entreprise
11-50 employés
Siège social
Paris, Ile-de-France
Type
Société civile/Société commerciale/Autres types de sociétés
Fondée en
2019
Domaines
Drug Discovery, Pharmaceutical, Deep Learning et Biotech

Lieux

Employés chez DeepLife

Nouvelles

Pages similaires

Parcourir les offres d’emploi

Financement

DeepLife 2 rounds en tout

Dernier round

Série A

5 971 801,00 $US

Voir plus d’informations sur Crunchbase